Dave Denton

Person

Mentions

Episodes

Claims

Dave Denton, mentioned 39 times across podcast episodes and expert conversations analyzed by Sonic.

What Dave Denton has said

The portfolio of assets acquired from Seagen is progressing ahead of Pfizer's initial expectations.

bullish·Dave Denton

Pfizer's adjusted gross margin for full-year 2025 was 76%.

neutral·Dave Denton

Pfizer deprioritized the development of disitamab vedotin in bladder cancer due to the strong clinical results and higher revenue projections for PADCEV.

mixed·Dave Denton

The portfolio of assets acquired from Seagen is progressing ahead of Pfizer's initial expectations.

Official sourceDave DentonApr 20

Pfizer's adjusted gross margin for full-year 2025 was 76%.

Official sourceDave DentonApr 20

Pfizer deprioritized the development of disitamab vedotin in bladder cancer due to the strong clinical results and higher revenue projections for PADCEV.

Official sourceDave DentonApr 20

In 2025, Pfizer invested $10.4 billion in internal R&D and approximately $8.8 billion in business development transactions.

Official sourceDave DentonApr 20

Pfizer has a 50/50 profit-sharing agreement with BioNTech for its COVID-19 vaccine, Comirnaty.

Official sourceDave DentonApr 20

Pfizer projects its core business, excluding COVID-19 products and products facing loss of exclusivity, will grow approximately 4% operationally year-over-year in 2026.

Official sourceDave DentonApr 20

Pfizer is reaffirming its full-year 2026 financial guidance.

Official sourceDave DentonApr 20

Pfizer's COVID-19 product revenue declined approximately 40% operationally year-over-year in Q4 2025.

Official sourceDave DentonApr 20

Pfizer projects its full-year 2026 adjusted diluted EPS to be in the range of $2.80 to $3.00 per share.

Official sourceDave DentonApr 20

For the full year 2025, Pfizer recorded revenues of $62.6 billion, a 2% operational decline from the previous year.

Official sourceDave DentonApr 20

Pfizer achieved approximately $600 million in savings through 2025 from Phase 1 of its manufacturing optimization program.

Official sourceDave DentonApr 20

In Q4 2025, Pfizer recorded revenues of $17.6 billion, a 3% operational decrease year-over-year.

Official sourceDave DentonApr 20

In Q4 2025, Pfizer recorded approximately $4.4 billion in non-cash intangible asset impairments related to development and in-line products.

Official sourceDave DentonApr 20

Pfizer projects its full-year 2026 revenues to be in the range of $59.5 billion to $62.5 billion.

Official sourceDave DentonApr 20

Pfizer is on track to deliver the majority of its targeted $7.2 billion in total net cost savings from productivity programs by the end of 2026.

Official sourceDave DentonApr 20

Pfizer's non-COVID product portfolio grew 9% operationally in Q4 2025 compared to the prior year.

Official sourceDave DentonApr 20

Pfizer expects its COVID-19 products to generate approximately $5 billion in revenue in 2026.

Official sourceDave DentonApr 20

Including the proceeds from the planned sale of its ViiV Healthcare stake, Pfizer will have approximately $7 billion in capacity for business development.

Official sourceDave DentonApr 20

Pfizer's portfolio of recently launched and acquired products generated $10.2 billion in revenue in 2025, growing approximately 14% operationally year-over-year.

Official sourceDave DentonApr 20

For the full year 2025, Pfizer reported a diluted EPS of $1.36 and an adjusted diluted EPS of $3.22.

Official sourceDave DentonApr 20

Create a free account to see Dave Denton's full intelligence report - every claim, the relationship network, and AI Q&A across all sources. No card needed.

Get started free

Back to Entities Entity Detail